These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35436334)

  • 1. Reactions to Amyloid PET Scan Results and Levels of Anxious and Depressive Symptoms: CARE IDEAS Study.
    Bélanger E; D'Silva J; Carroll MS; Van Houtven CH; Shepherd-Banigan M; Smith VA; Wetle TT
    Gerontologist; 2023 Jan; 63(1):71-81. PubMed ID: 35436334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?
    James HJ; Van Houtven CH; Lippmann S; Burke JR; Shepherd-Banigan M; Belanger E; Wetle TF; Plassman BL
    J Alzheimers Dis; 2020; 74(2):625-636. PubMed ID: 32065790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "I know that my role is going to change": a mixed-methods study of the relationship between amyloid-β PET scan results and caregiver burden.
    Couch E; Belanger E; Gadbois EA; DePasquale N; Zhang W; Wetle T
    Aging Clin Exp Res; 2023 Feb; 35(2):387-397. PubMed ID: 36484946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.
    Shepherd-Banigan ME; Ford CB; Smith VA; Belanger E; Wetle TT; Plassman BL; Burke JR; DePasquale N; O'Brien EC; Sorenson C; Van Houtven CH
    J Alzheimers Dis; 2022; 90(2):775-782. PubMed ID: 36189596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advance directives among cognitively impaired persons who had an amyloid PET scan and their care partners: a mixed-methods study.
    Bélanger E; Couch E; Carroll MS; DePasquale N; Gadbois EA; Shepherd-Banigan M; Jutkowitz E; Van Houtven CH; Plassman BL; Wetle TT
    BMC Palliat Care; 2022 Nov; 21(1):194. PubMed ID: 36336690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
    Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
    Rabinovici GD; Gatsonis C; Apgar C; Chaudhary K; Gareen I; Hanna L; Hendrix J; Hillner BE; Olson C; Lesman-Segev OH; Romanoff J; Siegel BA; Whitmer RA; Carrillo MC
    JAMA; 2019 Apr; 321(13):1286-1294. PubMed ID: 30938796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.
    Wang Y; Ren D; Roberts JS; Tamres LK; Lingler JH
    J Prev Alzheimers Dis; 2024; 11(4):958-965. PubMed ID: 39044506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between results of an amyloid PET scan and healthcare utilization in individuals with cognitive impairment.
    Jutkowitz E; Shewmaker P; Ford CB; Smith VA; O'Brien E; Shepherd-Banigan M; Belanger E; Plassman BL; Burke JR; Van Houtven CH; Wetle T
    J Am Geriatr Soc; 2024 Mar; 72(3):707-717. PubMed ID: 38069618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuity of care (COC) and amyloid-β PET scan: the CARE-IDEAS study.
    O'Brien EC; Ford CB; Sorenson C; Jutkowitz E; Shepherd-Banigan M; Van Houtven C
    Alzheimers Res Ther; 2023 Jan; 15(1):6. PubMed ID: 36611213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosocial and Behavioral Outcomes for Persons With Cognitive Impairment and Caregivers Following Amyloid-β PET Scan Disclosure: A Systematic Review.
    Couch E; Ashford MT; Zhang W; Prina M
    Alzheimer Dis Assoc Disord; 2023 Jul-Sep 01; 37(3):246-258. PubMed ID: 37561950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.
    Iaccarino L; La Joie R; Lesman-Segev OH; Lee E; Hanna L; Allen IE; Hillner BE; Siegel BA; Whitmer RA; Carrillo MC; Gatsonis C; Rabinovici GD
    JAMA Neurol; 2021 Feb; 78(2):197-207. PubMed ID: 33252608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
    Rabinovici GD; Carrillo MC; Apgar C; Gareen IF; Gutman R; Hanna L; Hillner BE; March A; Romanoff J; Siegel BA; Smith K; Song Y; Weber C; Whitmer RA; Gatsonis C
    JAMA Neurol; 2023 Nov; 80(11):1166-1173. PubMed ID: 37812437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
    Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
    JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
    Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
    Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.